

- Phentolamine (*Cont.*):
 for nerve agent exposure, 262e-5t
 for sympathomimetic overdose/poisoning, 473e-8t
- Phenylacetate, 434e-5
- Phenylalanine metabolism disorders, 434e-2t
- Phenylbutazones, 42t, 678
- Phenylephrine
 for allergic rhinitis, 2122
 for neurogenic shock, 1750
 overdose/poisoning with, 473e-8t
- Phenylketonuria
 clinical features of, 357t, 434e-1, 434e-2t
 environmental factors in, 437
 maternal, 434e-1
 prevalence of, 434e-1
 screening for, 434e-1
 treatment of, 434e-1
- Phenylpropanolamine, 3, 473e-8t
- Phenytol
 for acroparesthesia, 432e-1
 adverse effects of
 cross-sensitivity and, 385
 cutaneous, 352, 353, 360, 361
 fever, 138
 folate deficiency, 646t, 647
 gingival hyperplasia, 236
 hepatotoxicity, 2023, 2029, 2682t
 hirsutism, 332
 hypersensitivity, 382. *See also* Drug-induced hypersensitivity syndrome (DIHS)
 hypertrichosis, 380
 in kidney disease, 37
 long-term, 2552
 lupus syndrome, 2218t
 myopathy, 462e-20
 neurologic, 2554t, 2682t, 2687t
 osteopenia, 2218t
 systemic, 2554t
 thrombocytopenia, 727t
 vasculitis, 2193
- drug interactions of
 acetaminophen, 43
 azoles, 246e-3t
 cyclosporine, 42t
 fluoxetine, 2554t
 glipizide, 34t
 isoniazid, 205e-3
 losartan, 42, 42t
 methadone, 42t
 oral contraceptives, 42t
 PPIs, 1921
 quinidine, 42t, 246e-6t
 rufinamide, 2555t
 sulfonamides, 246e-4t, 2554t
 TMP-SMX, 939t
 warfarin, 42t
- for epilepsy, 2554t
 metabolism of, 34t, 40
 for myotonia, 462e-11
 for neuromyotonia, 619
 for neuropathy, 2682t
 overdose/poisoning with, 473e-10t, 2765t
 for pain, 91t, 94, 2672
 for paroxysmal symptoms in MS, 2672
 pharmacology of, 2552, 2554t
 for status epilepticus, 1735, 2558f
 therapeutic monitoring of, 2765t
 for trigeminal neuralgia, 2646
- Pheochromocytoma, **2329**
 clinical features of, **2329**
 cardiac, 254, 290e-1t, 290e-3, 1563
 by frequency of occurrence, 2330t
 hypertension, 1613, 1620t
 paraneoplastic syndromes, 610
 sympathetic overactivity, 2342, 2643
 definition of, 2329
 diagnosis of, 2329–2330, 2330t, 2341f, 2342
 differential diagnosis of, 2330
 epidemiology of, 2329
 etiology of, 2329
 familial, 1619, 2334
- genetic considerations in, **2329**
 mutation distribution, 2334–2335, 2334f
RET gene mutations, 1619, 1620t
 malignant, 2331
 in MEN syndromes, 1619, 1620t, 2332, 2332f, 2342
 in neurofibromatosis, 1619, 1620t, 2331–2332, 2331f, 2343
 in paraganglioma syndrome, 2332, 2333f
 pathogenesis of, 2329, 2330f
 during pregnancy, 2331
 renal cell carcinoma and, 578
 treatment of, 1619, 2330–2331
 tumor markers in, 473t
 in von Hippel-Lindau syndrome, 2332, 2333f
- Pheomelanin, 388
- PHEX* gene mutations, 2458
- Philadelphia chromosome
 in AML, 83e-1
 in CML, 101e-3, 101e-4f, 687–688, 688f, 689
 drug response and, 39t, 41
- Phlebectasia corona, 1651
- Phlebotomy
 for cyanotic CHD, 1523
 for erythrocytosis, 612
 for hemochromatosis, 367e-2, 2518
 for hemoglobinopathies, 637
 for polycythemia, 400, 674
 for porphyria cutanea tarda, 367e-3, 390, 2530
- Phleboviruses, 1305, 1309–1310t
- Phlebovirus infections
 Punta Toro virus, 1318
 Rift Valley fever. *See* Rift Valley fever
 sandfly fever, 1310t, 1318
 severe fever with thrombocytopenia syndrome, 1322
 Toscana virus, 894
- Phobic disorders, **2712**
- Phonemic paraphasia, 177
- Phoneutria* spp., 2748
- Phonic tics, 2623
- PhoP/PhoQ* genes, 145e-7
- Phosgene, 262e-1t
- Phosgene exposure, 1692t
- Phosgene oxime, 262e-1, 262e-1t
- Phosphate crystals, in urine, 62e-12f
- Phosphate nephropathy, 62e-11f, 1859
- Phosphate/phosphorus
 in chronic kidney disease, 333e-3, 333e-3f
 deficiency of. *See* Hypophosphatemia
 for diabetic ketoacidosis, 64e-2
 excess of. *See* Hyperphosphatemia
 for hypercalcemia, 610, 2480t, 2481
 metabolism of, 2458
 parenteral requirement for, 98e-5t
 phosphorus-32 exposure, 263e-3t
 recommended intake of, 95e-3t
 reference values for, 2762t
 renal tubular transport of, 332e-3f, 332e-7
 tolerable upper intake level of, 96e-9t
 toxicity of, 96e-9t
- Phosphatidylinositol-3-kinase (PI3K), 102e-6, 2403
- Phosphatonin, ectopic production of, 609t, 612
- Phosphodiesterase type 5 inhibitors
 action of, 324, 325f, 326f
 adverse effects of, 329t
 characteristics of, 329t
 contraindications to, 329t
 for erectile dysfunction, 324, 329t
 for female sexual dysfunction, 331
 for high-altitude pulmonary edema, 476e-3, 476e-4
 interaction with nitrates, 43, 328, 1596, 1603
 for lower urinary tract symptoms, 7e-4, 587
 for pulmonary arterial hypertension, 1659, 1660, 1660t, 2164
 for Raynaud's phenomenon, 1649, 2164
- Phosphofruktokinase deficiency (type VII
 glycogenosis; Tarui's disease), 433e-2t, 462e-14, 654t
- Phosphoglycerate dehydrogenase deficiency, 434e-2t
- Phosphoglycerate kinase deficiency, 433e-2t, 462e-14, 654t
- Phosphoglycerate mutase deficiency (type X
 GSD), 433e-2t, 462e-14
- Phospholamban, 265e-4, 265e-7, 265e-7f
- Phospholipase A₂, 126, 386
- Phospholipid transfer protein (PLTP), 2438
- Phosphoribosylpyrophosphate (PRPP), 431e-2
- Phosphoribosylpyrophosphate (PRPP)
 synthetase overactivity, 431e-3t, 431e-5
- Phosphorylate kinase deficiency (type IX
 glycogenosis), 332e-7t, 433e-2t, 433e-4, 462e-14
- Photoaging, 387
- Photoallergy, 389–390, 389t
- Photochemotherapy, 391
- Photodynamic therapy
 action of, 386
 for basal cell carcinoma, 501
 for cholangiocarcinoma, 553
- Photon, 103e-4
- Photopatch testing, 389
- Photoproducts, 386
- Photoprotection, 391, 391t. *See also* Sunscreen(s)
- Photoreceptors, 195
- Photosensitivity diseases, **388**
 classification of, 389t
 diagnosis of, 390f
 drug-induced, 379, 379f, 389–390, 389t
 management of, 390
 polymorphous light eruption, 364t, 366, 388–389
 porphyrias. *See* Porphyria(s)
 in SLE, 2129t
- Photosensitizer, 389
- Phototherapy. *See also* PUVA
 photochemotherapy
 action of, 391
 adverse effects of, 391
 for atopic dermatitis, 354t
 for cancer treatment of, 103e-5
 for morphea, 376
 for pityriasis rosea, 349
 for psoriasis, 348, 354t
 for psoriatic arthritis, 2177
 for shift-work disorder, 194
 for vitiligo, 358t
- Phototoxic eruptions, 361
- Phototoxicity, 389–390, 389t. *See also* Photosensitivity diseases
- PHP. *See* Pseudohypoparathyroidism (PHP)
- PHQ-2 (Patient Health Questionnaire-2)
 Depression Screen, 471e-5t
- Phrygian cap, 2076
- Phthalocyanines, 103e-5
- Phthisis. *See* Tuberculosis (TB)
- Phylloquinone, 96e-8. *See also* Vitamin K
- Phylogenetic analysis, 86e-1t
- Phylogenetic diversity, 86e-4–5
- Phylogenetic tree, 86e-1t
- Phylotype, 86e-1t, 86e-2
- Physical activity
 energy required for, 95e-1. *See also* Exercise
 for lifespan enhancement, 94e-7
- Physical examination
 clinical skills, 1–2
 screening tests, 26–27, 29t
- Physical restraints, in delirium, 65, 166, 170
- Physical therapy
 for back pain, 120
 for vertigo, 151t
- Physician
 brain drain, 13–14
 as citizen, 7
 claims of conscience by, 17e-2
 conflicts of interest for, 17e-3–4
 continuing education for, 7
 errors of, 4, 12e-1, 17e-4
 humanistic qualities of, 5
 impaired, 17e-4
 moral distress of, 17e-2–3
 oaths and codes of, 17e-2
 occupational risks of, 17e-4
 personal values of, 17e-2–3